Sökning: onr:"swepub:oai:DiVA.org:uu-366942" > Recurrence, progres...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06049naa a2200685 4500 | |
001 | oai:DiVA.org:uu-366942 | |
003 | SwePub | |
008 | 181128s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3669422 URI |
024 | 7 | a https://doi.org/10.1007/s00345-018-2299-22 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Palou, J.u Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain4 aut |
245 | 1 0 | a Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG :b not as bad as previously thought |
264 | c 2018-05-02 | |
264 | 1 | b SPRINGER,c 2018 |
338 | a print2 rdacarrier | |
520 | a Purpose: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG.Methods: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model.Results:During a median follow-up of 5.2years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P<0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P<0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen.Conclusions: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Non-muscle invasive bladder cancer | |
653 | a Re-transurethral resection of the bladder | |
653 | a Recurrence | |
653 | a Progression | |
700 | 1 | a Pisano, F.u Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain;Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 aut |
700 | 1 | a Sylvester, R.u EORTC Headquarters, Dept Biostat, Brussels, Belgium4 aut |
700 | 1 | a Joniau, S.u Univ Hosp Leuven, Oncol & Reconstruct Urol, Dept Urol, Louvain, Belgium4 aut |
700 | 1 | a Serretta, V.u Univ Palermo, Dept Surg Oncol & Stomatol Sci, Palermo, Italy4 aut |
700 | 1 | a Larre, S.u Univ Oxford, John Radcliffe Hosp, Dept Surg Sci, Oxford, England4 aut |
700 | 1 | a Di Stasi, S.u Policlin Tor Vergata Univ Rome, Rome, Italy4 aut |
700 | 1 | a van Rhijn, B.u Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands4 aut |
700 | 1 | a Witjes, A. J.u Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands4 aut |
700 | 1 | a Grotenhuis, A.u Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands4 aut |
700 | 1 | a Colombo, R.u Univ Vita Salute, Osped S Raffaele, Dipartimento Urol, Milan, Italy4 aut |
700 | 1 | a Briganti, A.u Univ Vita Salute, Osped S Raffaele, Dipartimento Urol, Milan, Italy4 aut |
700 | 1 | a Babjuk, M.u Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic4 aut |
700 | 1 | a Soukup, V.u Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic4 aut |
700 | 1 | a Malmström, Per-Unou Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)perunoms |
700 | 1 | a Irani, J.u Univ Poitiers, Dept Urol, Ctr Hosp Univ Mil, Poitiers, France4 aut |
700 | 1 | a Malats, N.u Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain4 aut |
700 | 1 | a Baniel, J.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel4 aut |
700 | 1 | a Mano, R.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel4 aut |
700 | 1 | a Cai, T.u Santa Chiara Hosp, Dept Urol, Trento, Italy4 aut |
700 | 1 | a Cha, E. K.u Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA4 aut |
700 | 1 | a Ardelt, P.u Chirurg Univ Klin, Facharzt Urol, Urol Abt, Freiburg, Germany4 aut |
700 | 1 | a Varkarakis, J.u Univ Athens, Sismanoglio Hosp, Dept Urol, Athens, Greece4 aut |
700 | 1 | a Bartoletti, R.u Univ Florence, Dept Expt & Clin Med, Florence, Italy4 aut |
700 | 1 | a Dalbagni, G.u Mem Sloan Kettering Canc Ctr, Dept Urol, 1275 York Ave, New York, NY 10021 USA4 aut |
700 | 1 | a Shariat, S. F.u Med Univ Vienna, Vienna, Austria4 aut |
700 | 1 | a Xylinas, E.u Cochin Hosp, Dept Urol, Paris, France4 aut |
700 | 1 | a Karnes, R. J.u Mayo Clin, Dept Urol, Rochester, MN USA4 aut |
700 | 1 | a Gontero, P.u Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 aut |
710 | 2 | a Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spainb Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain;Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 org |
773 | 0 | t World journal of urologyd : SPRINGERg 36:10, s. 1621-1627q 36:10<1621-1627x 0724-4983x 1433-8726 |
856 | 4 | u https://art.torvergata.it/bitstream/2108/213079/1/World%20Journal%20of%20Urology%202018_36_1621_1627.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-366942 |
856 | 4 8 | u https://doi.org/10.1007/s00345-018-2299-2 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.